1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Croatia Pharmaceuticals and Healthcare Report Q1 2017

Croatia Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 79 pages

Includes 3 FREE quarterly updates

BMI View:
The Croatian government's healthcare policies will remain mired in uncertainty given the HDZMost coalition is set to be reformed following a snap election brought about by the collapse of the same alliance in June. Although the healthcare sector is in dire need of structural reforms, political instability is likely to undermine this. The need to reduce the public deficit will also increase pressure on the healthcare system.

Headline Expenditure Projections


- Pharmaceuticals: HRK6.73bn (USD857mn) in 2015 to HRK6.85bn (USD948mn) in 2016; 1.8% in local currency and 10.6% in US dollar terms. Forecast revised upward compared to previous quarter.

- Healthcare: HRK26.2bn (USD3.34bn) in 2015 to HRK26.9bn (USD3.72bn) in 2016; 2.5% in local currency and 11.4% in US dollar terms. Forecast revised upward compared to previous quarter. Despite its accession to the EU, Croatia offers little in the way of growth prospects over the long term. Croatia recorded a score of 48.4 out of 100 in our Q117 Risk/Reward Index (RRI), making it the 14th most attractive pharmaceutical market in Central and Eastern Europe. Croatia's RRI score this quarter stayed the same as in Q416 but it still remains poor owing to the depreciation of the Croatian kuna against the dollar and our concerns over the country's economic outlook impacting our pharmaceutical sales forecasts.

Table Of Contents

Croatia Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Croatia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Croatia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Croatia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Croatia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Croatia 2012-2020) 16
Prescription Drug Market 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 23
OTC Medicines Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Croatia 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Croatia 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Croatia 2014-2020) 28
Industry Risk Reward Index 29
Central And Eastern Europe Risk/Reward Index - Q1 2017 29
Croatia Risk/Reward Index 36
Rewards 36
Risks 37
Regulatory Review 38
Intellectual Property Issues 41
Pricing Regime 42
Table: Profit Margins For Wholesalers 43
Reimbursement Regime 43
Market Overview 46
Healthcare Sector 47
Table: Healthcare Resources (Croatia 2010-2015) 47
Table: Healthcare Personnel (Croatia 2010-2015) 48
Table: Healthcare Activity (Croatia 2010-2015) 48
Table: Reimbursed Drug Expenditure By HZZO (HRKbn) - Equivalent To Final Consumer Prices 49
Research and Development 50
Clinical Trials 51
Epidemiology 52
Table: Cancer Incidence Rates, 2012-2035 54
Competitive Landscape 56
Research-Based Industry 56
Table: Multinational Market Activity 57
Generic Drugmakers 58
Pharmaceutical Distribution 58
Pharmaceutical Retail 59
Company Profile 60
Belupo 60
Jadran Galenski Laboratorij 63
PLIVA 65
Demographic Forecast 68
Table: Population Headline Indicators (Croatia 1990-2025) 69
Table: Key Population Ratios (Croatia 1990-2025) 69
Table: Urban/Rural Population and Life Expectancy (Croatia 1990-2025) 70
Table: Population By Age Group (Croatia 1990-2025) 70
Table: Population By Age Group % (Croatia 1990-2025) 71
Glossary 73
Methodology 75
Pharmaceutical Expenditure Forecast Model 75
Healthcare Expenditure Forecast Model 75
Notes On Methodology 76
Risk/Reward Index Methodology 77
Index Overview 78
Table: Pharmaceutical Risk/Reward Index Indicators 78
Indicator Weightings 79

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.